Herbion Brečtan

Herbion Brečtan is an over‑the‑counter oral product that contains a dry extract of Hederae folium (ivy leaf) standardized to a 5‑7.5:1 ratio and prepared with 30 % ethanol (m/m) as the extraction solvent. Marketed in the European Union, the preparation is supplied as a dry herbal extract intended for respiratory support and is packaged in dosage‑controlled containers for short‑term use under professional guidance and appropriate monitoring.

Herbion Brečtan is traditionally used to alleviate symptoms associated with common respiratory conditions.

- Relief of occasional dry or productive cough. - Supportive care in acute bronchitis. - Adjunctive treatment for mild upper respiratory tract infections. - Soothing of throat irritation during laryngitis. - Management of post‑viral airway inflammation. - Reduction of mild wheezing associated with airway irritation. - Facilitation of mucus clearance in early‑stage cough. - Symptomatic relief during seasonal colds.

Adverse reactions to Herbion Brečtan are generally uncommon, but they can occur.

Common: - Mild gastrointestinal discomfort such as nausea or stomach upset. - Transient oral irritation or a bitter taste. - Slight headache or dizziness. - Mild skin rash or itching at the site of contact. - Mild increase in heart rate. - Temporary dry mouth.

Serious: - Allergic reactions including swelling of the face, lips, or throat. - Severe bronchospasm or difficulty breathing. - Hepatotoxicity manifested by jaundice (very rare). - Anaphylactic shock (extremely rare). - Severe abdominal pain or cramping.

Most users tolerate the product well, and side effects are usually mild and reversible. If any reaction persists, medical advice should be sought promptly.

Precautions for using Herbion Brečtan focus on patient safety and appropriate selection.

- Not recommended for children under 6 years of age unless advised by a physician. - Use with caution in individuals with known hypersensitivity to ivy or related plants. - Avoid during pregnancy and breastfeeding due to insufficient safety data. - Patients with severe liver or kidney disease should consult a healthcare professional before use. - Do not exceed the recommended duration of therapy, typically not longer than two weeks without medical supervision. - Concomitant use with other mucolytic or bronchodilator agents should be discussed with a clinician.

Herbion Brečtan may interact with certain medications or substances; awareness of these interactions helps minimize risk.

Avoid: - Concurrent use with potent CYP450 enzyme inhibitors, as they may increase systemic exposure to ivy constituents. - Combining with other herbal expectorants or mucolytics without medical guidance, which could amplify effects.

Use with caution: - Use cautiously with anticoagulant or antiplatelet drugs due to potential mild platelet inhibition. - Monitor when taken alongside beta‑agonist bronchodilators, as additive bronchodilatory effects may occur. - Caution is advised when combined with antihistamines that may cause additive sedation or dry mouth. - Avoid alcohol consumption as it may increase the risk of gastrointestinal irritation.